BeiGene, USA Inc. – FDA 483, Nov 13, 2023
An FDA inspection of BEIGENE USA INC in San Mateo, CA, revealed significant deficiencies in their pharmacovigilance and clinical trial oversight. The firm failed to timely report serious adverse drug experiences, lacked written procedures for post-marketing surveillance from social media, and exhibited inadequate monitoring of clinical studies leading to delayed reporting of safety events and unresolved data queries. These issues indicate a systemic failure to comply with regulatory requirements for drug safety and clinical research.
ID · 9c8f2383-af4e-4b58-b663-779863e3ef9c
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.